Relaxin: New Pathophysiological aspects and pharmacological perspectives for an old protein

Medicinal Research Reviews

Volumn 34, Issue 1, 2014, Pages 77-105

  Cernaro, Valeria ^a   Lacquaniti, Antonio ^a   Lupica, Rosaria ^a   Buemi, Antoine ^a   Trimboli, Domenico ^a   Giorgianni, Grazia ^a   Bolignano, Davide ^b   Buemi, Michele ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

New drugs; Pleiotropic hormone; Relaxin; Relaxin family peptide (RXFP) receptors

Indexed keywords

ANTIFIBROTIC AGENT; ERYTHROPOIETIN; GROWTH FACTOR; RELAXIN; TRANSFORMING GROWTH FACTOR BETA1;

ANGIOGENESIS; ARTICLE; BIOLOGICAL ACTIVITY; BODY FLUID; BONE REMODELING; BONE TISSUE; CENTRAL NERVOUS SYSTEM; FIBROSIS; HEART FAILURE; HEMODYNAMICS; HOMEOSTASIS; HUMAN; HYPERTENSION; NEOPLASM; NONHUMAN; PATHOPHYSIOLOGY; PLEIOTROPY; PREECLAMPSIA; PREGNANCY; SEX DIFFERENCE;

NEW DRUGS; PLEIOTROPIC HORMONE; RELAXIN; RELAXIN FAMILY PEPTIDE (RXFP) RECEPTORS;

BODY FLUIDS; FEMALE; HEART FAILURE; HEMODYNAMICS; HOMEOSTASIS; HUMANS; HYPERTENSION; KIDNEY; MALE; PREGNANCY; RELAXIN;

EID: 84892165173     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21277     Document Type: Article

References (176)

1. Hossain MA, Rosengren KJ, Samuel CS, Shabanpoor F, Chan LJ, Bathgate RA, Wade JD. The minimal active structure of human relaxin-2. J Biol Chem 2011;286(43):37555-37565.
2. McGuane JT, Debrah JE, Debrah DO, Rubin JP, Segal M, Shroff SG, Conrad KP. Role of relaxin in maternal systemic and renal vascular adaptations during gestation. Ann N Y Acad Sci 2009;1160:304-312.
3. Dschietzig T, Bartsch C, Baumann G, Stangl K. Relaxin-a pleiotropic hormone and its emerging role for experimental and clinical therapeutics. Pharmacol Ther 2006;112(1):38-56.
4. Kong RC, Shilling PJ, Lobb DK, Gooley PR, Bathgate RA. Membrane receptors: Structure and function of the relaxin family peptide receptors. Mol Cell Endocrinol 2010;320(1-2):1-15.
5. Hsu SY, Nakabayashi K, Nishi S, Kumagai J, Kudo M, Sherwood OD, Hsueh AJ. Activation of orphan receptors by the hormone relaxin. Science 2002;295(5555):671-674.
6. Kumagai J, Hsu SY, Matsumi H, Roh JS, Fu P, Wade JD, Bathgate RA, Hsueh AJ. INSL3/Leydig insulin-like peptide activates the LGR8 receptor important in testis descent. J Biol Chem 2002;277(35):31283-31286.
7. Smith CM, Ryan PJ, Hosken IT, Ma S, Gundlach AL. Relaxin-3 systems in the brain-the first 10 years. J Chem Neuroanat 2011;42(4):262-275.
8. Belgi A, Hossain MA, Shabanpoor F, Chan L, Zhang S, Bathgate RA, Tregear GW, Wade JD. Structure and function relationship of murine insulin-like peptide 5 (INSL5): Free C-terminus is essential for RXFP4 receptor binding and activation. Biochemistry 2011;50(39):8352-8361.
9. Zhu J, Kuei C, Sutton S, Kamme F, Yu J, Bonaventure P, Atack J, Lovenberg TW, Liu C. Identification of the domains in RXFP4 (GPCR142) responsible for the high affinity binding and agonistic activity of INSL5 at RXFP4 compared to RXFP3 (GPCR135). Eur J Pharmacol 2008;590(1-3):43-52.
10. Sunder S, and Lenton EA. Endocrinology of the peri-implantation period. Baillieres Best Pract Res Clin Obstet Gynaecol 2000;14:789-800.
11. Bani D, Ballati L, Masini E, Bigazzi M, Sacchi TB. Relaxin counteracts asthma-like reaction induced by inhaled antigen in sensitized guinea pigs. Endocrinology 1997;138:1909-1915.
12. Masini E, Zagli G, Ndisang JF, Solazzo M, Mannaioni PF, Bani D. Protective effect of relaxin in cardiac anaphylaxis: Involvement of the nitric oxide pathway. Br J Pharmacol 2002;137:337-344.
13. Piccinni MP, Bani D, Beloni L, Manuelli C, Mavilia C, Vocioni F, Romagnani S, Maggi E. Relaxin favors the development of activated human T cells into Th1-like effectors. Eur J Immunol 1999;29:2241-2247.
14. Dayanithi G, Cazalis M, Nordmann JJ. Relaxin affects the release of oxytocin and vasopressin from the neurohypophysis. Nature 1987;325:813-816.
15. Way SA, Leng G. Relaxin increases the firing rate of supraoptic neurones and increases oxytocin secretion in the rat. J Endocrinol 1992;132:149-158.
16. Neumann ID. Involvement of the brain oxytocin system in stress coping: Interactions with the hypothalamo-pituitary-adrenal axis. Prog Brain Res 2002;139:147-162.
17. Watters JJ, Poulin P, Dorsa DM. Steroid hormone regulation of vasopressinergic neurotransmission in the central nervous system. Prog. Brain Res 1998;119:247-261.
18. Seibold JR, Korn JH, Simms R, Clements PJ, Moreland LW, Mayes MD, Furst DE, Rothfield N, Steen V, Weisman M, Collier D, Wigley FM, Merkel PA, Csuka ME, Hsu V, Rocco S, Erikson M, Hannigan J, Harkonen WS, Sanders ME. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000;132(11):871-879.
19. Dschietzig T, Bartsch C, Stangl V, Baumann G, Stangl K. Identification of the pregnancy hormone relaxin as glucocorticoid receptor agonist. FASEB J 2004;18(13):1536-1538.
20. Bièche I, Laurent A, Laurendeau I, Duret L, Giovangrandi Y, Frendo JL, Olivi M, Fausser JL, Evain-Brion D, Vidaud M. Placenta-specific INSL4 expression is mediated by a human endogenous retrovirus element. Biol Reprod 2003;68(4):1422-1429.
21. Millar L, Streiner N, Webster L, Yamamoto S, Okabe R, Kawamata T, Shimoda J, Büllesbach E, Schwabe C, Bryant-Greenwood G. Early placental insulin-like protein (INSL4 or EPIL) in placental and fetal membrane growth. Biol Reprod 2005;73(4):695-702.
22. Burnicka-Turek O, Shirneshan K, Paprotta I, Grzmil P, Meinhardt A, Engel W, Adham IM. Inactivation of insulin-like factor 6 disrupts the progression of spermatogenesis at late meiotic prophase. Endocrinology 2009;150(9):4348-4357.
23. Lu C, Walker WH, Sun J, Weisz OA, Gibbs RB, Witchel SF, Sperling MA, Menon RK. Insulin-like peptide 6: Characterization of secretory status and posttranslational modifications. Endocrinology 2006;147(12):5611-5623.
24. Talmage RV. Histological effects of estradiol, progesterone, and relaxin on the symphysis pubis of the guinea pig. Anat Rec 1946;96(4):528.
25. Perl E, Catchpole HR. Changes induced in the connective tissue of the pubic symphysis of the guinea pig with estrogen and relaxin. Arch Pathol (Chic) 1950;50(2):233-239.
26. Talmage RV. The role of estrogen in the estrogen-relaxin relationship in relaxation of the symphysis pubis of the guinea pig. Anat Rec 1947;99(4):571.
27. Trentin JJ. Relaxin and mammary growth in the mouse. Proc Soc Exp Biol Med 1951;78(1):9-11.
28. Garrett FA, Talmage RV. The influence of relaxin on mammary gland development in guinea-pigs and rabbits. J Endocrinol 1952;8(4):336-340.
29. Sawyer WH, Frieden EH, Martin AC. In vitro inhibition of spontaneous contractions of the rat uterus by relaxin-containing extracts of sow ovaries. Am J Physiol 1953;172(3):547-552.
30. Zarrow MX, Neher GM, Sikes D, Brennan DM, Bullard JF. Dilatation of the uterine cervix of the sow following treatment with relaxin. Am J Obstet Gynecol 1956;72(2):260-264.
31. Posse N. Relaxin and its effect on uterine motility. Nord Med 1957;57(19):678-680.
32. Eichner E, Waltner C, Goodman M, Post S. Relaxin, the third ovarian hormone: Its experimental use in women. Am J Obstet Gynecol 1956;71(5):1035-1048.
33. Frieden EH, Hisaw FL. The purification of relaxin. Arch Biochem 1950;29(1):166-178.
34. Zarrow MX. Relaxin content of blood, urine and other tissues of pregnant and postpartum guinea pigs. Proc Soc Exp Biol Med 1947;66(2):488-491.
35. Yki-Järvinen H, Wahlström T, Seppälä M. Immunohistochemical demonstration of relaxin in the genital tract of men. J Reprod Fertil 1983;69(2):693-695.
36. Fuchs U. The effect of relaxin and ubiquitin on sperm motility. Zentralbl Gynakol 1993;115(3):117-120.
37. Beiler JM, McBurney EA, Pachtman EA, Pizzaia LM, Martin GJ. Effects of relaxin on wound healing. Arch Int Pharmacodyn Ther 1960;123:291-294.
38. Bradham GB, StallWorth JM, Brailsford LE, Threatt BA. Clinical evaluation of relaxin in ulcerative ischemic vascular or collagen diseases. Angiology 1962;13:418-420.
39. Tranquada RE, Simmons DH, Miller JH. Pulmonary fibrosis in scleroderma: Report of a case with pulmonary function studies to evaluate corticosteroid and relaxin therapy. Arch Intern Med 1960;105:607-612.
40. McMurtry JP, Floersheim GL, Bryant-Greenwood GD. Characterization of the binding of 125I-labelled succinylated porcine relaxin to human and mouse fibroblasts. J Reprod Fertil 1980;58(1):43-49.
41. Weiss M, Nagelschmidt M, Struck H. Relaxin and collagen metabolism. Horm Metab Res 1979;11(6):408-410.
42. Borel JP. Uterine collagens. General review. Rev Fr Gynecol Obstet 1991;86(12):715-722.
43. St-Louis J, Massicotte G. Chronic decrease of blood pressure by rat relaxin in spontaneously hypertensive rats. Life Sci 1985;37(14):1351-1357.
44. Massicotte G, Parent A, St-Louis J. Blunted responses to vasoconstrictors in mesenteric vasculature but not in portal vein of spontaneously hypertensive rats treated with relaxin. Proc Soc Exp Biol Med 1989;190(3):254-259.
45. Bani D, Failli P, Bello MG, Thiemermann C, Bani Sacchi T, Bigazzi M, Masini E. Relaxin activates the L-arginine-nitric oxide pathway in vascular smooth muscle cells in culture. Hypertension 1998;31(6):1240-1247.
46. Kakouris H, Eddie LW, Summers RJ. Cardiac effects of relaxin in rats. Lancet 1992;339(8801):1076-1078.
47. Bani-Sacchi T, Bigazzi M, Bani D, Mannaioni PF, Masini E. Relaxin-induced increased coronary flow through stimulation of nitric oxide production. Br J Pharmacol 1995;116(1):1589-1594.
48. Taylor MJ, Clark CL. Evidence for a novel source of relaxin: Atrial cardiocytes. J Endocrinol 1994;143(2):R5-R8.
49. Tashima LS, Mazoujian G, Bryant-Greenwood GD. Human relaxins in normal, benign and neoplastic breast tissue. J Mol Endocrinol 1994;12(3):351-364.
50. Bigazzi M, Brandi ML, Bani G, Sacchi TB. Relaxin influences the growth of MCF-7 breast cancer cells. Mitogenic and antimitogenic action depends on peptide concentration. Cancer 1992;70(3):639-643.
51. Cornelis T, Odutayo A, Keunen J, Hladunewich M. The kidney in normal pregnancy and preeclampsia. Semin Nephrol 2011;31(1):4-14.
52. Jeyabalan A, Lain KY. Anatomic and functional changes of the upper urinary tract during pregnancy. Urol Clin North Am 2007;34(1):1-6.
53. Moulin B, Hertig A, Rondeau E; Collége national des gynécologues et obstétriciens; Société française de médecine périnatale; Société française de néonatalogie; Société française de anesthésie et de réanimation. Kidney and preeclampsia. Ann Fr Anesth Reanim 2010;29(4):e83-e90.
54. McGuane JT, Debrah JE, Debrah DO, Rubin JP, Segal M, Shroff SG, Conrad KP. Role of relaxin in maternal systemic and renal vascular adaptations during gestation. Ann N Y Acad Sci 2009;1160:304-312.
55. Conrad KP. Emerging role of relaxin in the maternal adaptations to normal pregnancy: Implications for preeclampsia. Semin Nephrol 2011;31(1):15-32.
56. Jeyabalan A, Conrad KP. Renal function during normal pregnancy and preeclampsia. Front Biosci 2007;12:2425-2437.
57. Conrad KP, Debrah DO, Novak J, Danielson LA, Shroff SG. Relaxin modifies systemic arterial resistance and compliance in conscious, nonpregnant rats. Endocrinology 2004;145:3289-3296.
58. Gilson GJ, Mosher MD, Conrad KP. Systemic hemodynamics and oxygen transport during pregnancy in chronically instrumented, conscious rats. Am J Physiol 1992;263:H1911-H1918.
59. Danielson LA, Sherwood OD, Conrad KP. Relaxin is a potent renal vasodilator in conscious rats. J Clin Invest 1999;103:525-533.
60. Conrad KP. Renal hemodynamics during pregnancy in chronically catheterized, conscious rats. Kidney Int 1984;26:24-29.
61. Chapman AB, Zamudio S, Woodmansee W, Merouani A, Osorio F, Johnson A, Moore LG, Dahms T, Coffin C, Abraham WT, Schrier RW. Systemic and renal hemodynamic changes in the luteal phase of the menstrual cycle mimic early pregnancy. Am J Physiol 1997;273(5 Pt 2):F777-F782.
62. Stewart DR, Celniker AC, Taylor CA Jr, Cragun JR, Overstreet JW, Lasley BL. Relaxin in the peri-implantation period. J Clin Endocrinol Metab 1990;70(6):1771-1773.
63. Dragoo JL, Castillo TN, Korotkova TA, Kennedy AC, Kim HJ, Stewart DR. Trends in serum relaxin concentration among elite collegiate female athletes. Int J Womens Health 2011;3:19-24.
64. Szlachter BN, Quagliarello J, Jewelewicz R, Osathanondh R, Spellacy WN, Weiss G. Relaxin in normal and pathogenic pregnancies. Obstet Gynecol 1982;59(2):167-170.
65. Hertig A, Liere P. New markers in preeclampsia. Clin Chim Acta 2010;411(21-22):1591-1595.
66. Conrad KP, Baker VL. Corpus Luteal Contribution to Maternal Pregnancy Physiology and Outcomes in Assisted Reproductive Technologies. Am J Physiol Regul Integr Comp Physiol 2013;304(2):R69-R72 [Epub ahead of print].
67. van Drongelen J, Ploemen IH, Pertijs J, Gooi JH, Sweep FC, Lotgering FK, Spaanderman ME, Smits P. Aging attenuates the vasodilator response to relaxin. Am J Physiol Heart Circ Physiol 2011;300(5):H1609-H1615.
68. Dechend R, Luft FC. Are we getting closer to a Nobel prize for unraveling preeclampsia? Curr Cardiol Rep 2008;10(6):440-447.
69. Davison JM, Homuth V, Jeyabalan A, Conrad KP, Karumanchi SA, Quaggin S, Dechend R, Luft FC. New aspects in the pathophysiology of preeclampsia. J Am Soc Nephrol 2004;15(9):2440-2448.
70. Unemori E, Sibai B, Teichman SL. Scientific rationale and design of a phase I safety study of relaxin in women with severe preeclampsia. Ann N Y Acad Sci 2009;1160:381-384.
71. Wang YQ, Li J, Yang Z. Expression of relaxin receptor in placental tissues of normal pregnancy and pre-eclampsia. Zhonghua Fu Chan Ke Za Zhi 2008;43(4):269-271.
72. Lafayette RA, Hladunewich MA, Derby G, Blouch K, Druzin ML, Myers BD. Serum relaxin levels and kidney function in late pregnancy with or without preeclampsia. Clin Nephrol 2011;75(3):226-232.
73. Kern A, Bryant-Greenwood GD. Mechanisms of relaxin receptor (LGR7/RXFP1) expression and function. Ann N Y Acad Sci 2009;1160:60-66.
74. Scott DJ, Layfield S, Yan Y, Sudo S, Hsueh AJ, Tregear GW, Bathgate RA. Characterization of novel splice variants of LGR7 and LGR8 reveals that receptor signaling is mediated by their unique low density lipoprotein class A modules. J Biol Chem 2006;281(46):34942-34954.
75. D'Anna R, Baviera G, Giordano D, Todarello G, Corrado F, Buemi M. Second trimester neutrophil gelatinase-associated lipocalin as a potential prediagnostic marker of preeclampsia. Acta Obstet Gynecol Scand 2008;87(12):1370-1373.
76. Buemi M, Bolignano D, Barilla A, Nostro L, Crasci E, Campo S, Coppolino G, D'Anna R. Preeclampsia and cardiovascular risk: General characteristics, counseling and follow-up. J Nephrol 2008;21(5):663-672.
77. Massicotte G, Parent A, St-Louis J. Blunted responses to vasoconstrictors in mesenteric vasculature but not in portal vein of spontaneously hypertensive rats treated with relaxin. Proc Soc Exp Biol Med 1989;190(3):254-259.
78. McGuane JT, Debrah JE, Sautina L, Jarajapu YP, Novak J, Rubin JP, Grant MB, Segal M, Conrad KP. Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide. Endocrinology 2011;152(7):2786-2796.
79. Dschietzig T, Richter C, Bartsch C, Laule M, Armbruster FP, Baumann G, Stangl K. The pregnancy hormone relaxin is a player in human heart failure. FASEB J 2001;15(12):2187-2195.
80. Gedikli O, Yilmaz H, Kiris A, Karaman K, Ozturk S, Baykan M, Ucar U, Durmus I, Karahan C, Celik S. Circulating levels of relaxin and its relation to cardiovascular function in patients with hypertension. Blood Press 2009;18(1-2):68-73.
81. Dschietzig T, Bartsch C, Richter C, Laule M, Baumann G, Stangl K. Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist. Attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-b receptor expression via ERK-1/2 and nuclear factor-κB. Circ Res 2003;92:32-40.
82. Yoshida T, Kumagai H, Suzuki A, Kobayashi N, Ohkawa S, Odamaki M, Kohsaka T, Yamamoto T, Ikegaya N. Relaxin ameliorates salt-sensitive hypertension and renal fibrosis. Nephrol Dial Transplant 2012;27(6):2190-2197.
83. Debrah DO, Debrah JE, Haney JL, McGuane JT, Sacks MS, Conrad KP, Shroff SG. Relaxin regulates vascular wall remodeling and passive mechanical properties in mice. J Appl Physiol 2011;111(1):260-271.
84. Jeyabalan A, Shroff SG, Novak J, Conrad KP. The vascular actions of relaxin. Adv Exp Med Biol 2007;612:65-87.
85. Chaykovska L, Tsuprykov O, Hocher B. Biomarkers for the prediction of mortality and morbidity in patients with renal replacement therapy. Clin Lab 2011;57(7-8):455-467.
86. Mi S, Hu ZW. Suppressing myocardial fibrosis to promote myocardial regeneration as a therapeutic strategy for chronic cardiovascular diseases. Sheng Li Ke Xue Jin Zhan 2010;41(5):352-358.
87. Sasser JM, Molnar M, Baylis C. Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N(ω)-nitro-L-arginine methyl ester hypertensive rats. Hypertension 2011;58(2):197-204.
88. Lekgabe ED, Kiriazis H, Zhao C, Xu Q, Moore XL, Su Y, Bathgate RA, Du XJ, Samuel CS. Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension 2005;46(2):412-418.
89. Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD, Marmor A, Katz A, Grzybowski J, Unemori E, Teichman SL, Cotter G. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): A multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009;373(9673):1429-1439 [Comment in Lancet 2009;373(9673):1401-1402].
90. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M; for the RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): A randomised, placebo-controlled trial. Lancet 2012; pii: S0140-6736(12)61855-8.
91. Dschietzig T, Alexiou K, Kinkel HT, Baumann G, Matschke K, Stangl K. The positive inotropic effect of relaxin-2 in human atrial myocardium is preserved in end-stage heart failure: Role of G(i)-phosphoinositide-3 kinase signaling. J Card Fail 2011;17(2):158-166.
92. Du XJ, Bathgate RA, Samuel CS, Dart AM, Summers RJ. Cardiovascular effects of relaxin: From basic science to clinical therapy. Nat Rev Cardiol 2010;7(1):48-58.
93. Du XJ, Samuel CS, Gao XM, Zhao L, Parry LJ, Tregear GW. Increased myocardial collagen and ventricular diastolic dysfunction in relaxin deficient mice: A gender-specific phenotype. Cardiovasc Res 2003;57(2):395-404.
94. Hocher B, Ziebig R, Krause R, Asmus G, Neumayer HH, Liefeldt L, Stasch JP. Relaxin is an independent risk factor predicting death in male patients with end-stage kidney disease. Circulation 2004;109(19):2266-2268.
95. Du XJ, Samuel CS, Gao XM, Zhao L, Parry LJ, Tregear GW. Increased myocardial collagen and ventricular diastolic dysfunction in relaxin deficient mice: A gender-specific phenotype. Cardiovasc Res 2003;57(2):395-404.
96. Samuel CS, Unemori EN, Mookerjee I, Bathgate RA, Layfield SL, Mak J, Tregear GW, Du XJ. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 2004;145(9):4125-4133.
97. Samuel CS, Zhao C, Bond CP, Hewitson TD, Amento EP, Summers RJ. Relaxin-1-deficient mice develop an age-related progression of renal fibrosis. Kidney Int 2004;65(6):2054-2064.
98. Unemori EN, Bauer EA, Amento EP. Relaxin alone and in conjunction with interferon-gamma decreases collagen synthesis by cultured human scleroderma fibroblasts. J Invest Dermatol 1992;99(3):337-342.
99. Unemori EN, Beck LS, Lee WP, Xu Y, Siegel M, Keller G, Liggitt HD, Bauer EA, Amento EP. Human relaxin decreases collagen accumulation in vivo in two rodent models of fibrosis. J Invest Dermatol 1993;101(3):280-285.
100. Unemori EN, Pickford LB, Salles AL, Piercy CE, Grove BH, Erikson ME, Amento EP. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 1996;98(12):2739-2745.
101. Garber SL, Mirochnik Y, Brecklin CS, Unemori EN, Singh AK, Slobodskoy L, Grove BH, Arruda JA, Dunea G. Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int 2001;59(3):876-882.
102. Samuel CS, Sakai LY, Amento EP. Relaxin regulates fibrillin 2, but not fibrillin 1, mRNA and protein expression by human dermal fibroblasts and murine fetal skin. Arch Biochem Biophys 2003;411(1):47-55.
103. Bennett RG, Kharbanda KK, Tuma DJ. Inhibition of markers of hepatic stellate cell activation by the hormone relaxin. Biochem Pharmacol 2003;66(5):867-874.
104. Samuel CS, Lekgabe ED, Mookerjee I. The effects of relaxin on extracellular matrix remodeling in health and fibrotic disease. Adv Exp Med Biol 2007;612:88-103.
105. Unemori EN, Amento EP.Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts. J Biol Chem 1990;265(18):10681-10685.
106. Gavino ES, Furst DE. Recombinant relaxin: A review of pharmacology and potential therapeutic use. BioDrugs 2001;15(9):609-614.
107. Furst DE. Rational therapy in the treatment of systemic sclerosis. Curr Opin Rheumatol 2000;12(6):540-544.
108. Steen VD. Treatment of systemic sclerosis. Am J Clin Dermatol 2001;2(5):315-325.
109. Liu T, Hu XD. Studies on the fibroblast proliferation and transdifferentiation for myofibroblast from skin lesion of the patients with systemic sclerosis repressed by H2 Relaxin. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2011;27(12):1312-1214.
110. Williams EJ, Benyon RC, Trim N, Hadwin R, Grove BH, Arthur MJ, Unemori EN, Iredale JP. Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo. Gut 2001;49(4):577-583.
111. Samuel CS, Zhao C, Bathgate RA, Bond CP, Burton MD, Parry LJ, Summers RJ, Tang ML, Amento EP, Tregear GW. Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosis. FASEB J 2003;17(1):121-123.
112. Kenyon NJ, Ward RW, Last JA. Airway fibrosis in a mouse model of airway inflammation. Toxicol Appl Pharmacol 2003;186(2):90-100.
113. Hewitson TD, Samuel CS. Relaxin: An endogenous renoprotective factor? Ann N Y Acad Sci 2009;1160:289-293.
114. Garber SL, Mirochnik Y, Brecklin C, Slobodskoy L, Arruda JA, Dunea G. Effect of relaxin in two models of renal mass reduction. Am J Nephrol 2003;23(1):8-12.
115. Hewitson TD, Ho WY, Samuel CS. Antifibrotic properties of relaxin: In vivo mechanism of action in experimental renal tubulointerstitial fibrosis. Endocrinology 2010;151(10):4938-4948.
116. Mookerjee I, Hewitson TD, Halls ML, Summers RJ, Mathai ML, Bathgate RA, Tregear GW, Samuel CS. Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J 2009;23(4):1219-1229.
117. Samuel CS, Hewitson TD. Relaxin and the progression of kidney disease. Curr Opin Nephrol Hypertens 2009;18(1):9-14.
118. Santibañez JF, Quintanilla M, Bernabeu C. TGF-β/TGF-β receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 2011;121(6):233-251.
119. Hossain MA, Man BC, Zhao C, Xu Q, Du XJ, Wade JD, Samuel CS. H3 relaxin demonstrates antifibrotic properties via the RXFP1 receptor. Biochemistry 2011;50(8):1368-1375.
120. Samuel CS, Mookerjee I, Halls ML, Summers RJ, Chew E, Bathgate RA, Tregear GW, Hewitson TD. Investigations into the inhibitory effects of relaxin on renal myofibroblast differentiation. Ann N Y Acad Sci 2009;1160:294-299.
121. Pini A, Shemesh R, Samuel CS, Bathgate RA, Zauberman A, Hermesh C, Wool A, Bani D, Rotman G. Prevention of bleomycin-induced pulmonary fibrosis by a novel antifibrotic peptide with relaxin-like activity. J Pharmacol Exp Ther 2010;335(3):589-599.
122. Wen Y, Zhao YY, Polan ML, Chen B. Effect of relaxin on TGF-beta1 expression in cultured vaginal fibroblasts from women with stress urinary incontinence. Reprod Sci 2008;15(3):312-320.
123. Taylor MJ, Clark CL. Transforming growth factor-beta is a potent inhibitor of basal and stimulated relaxin release by porcine luteal cells maintained in monolayer culture. J Endocrinol 1992;135(3):543-550.
124. Buemi M, Galeano M, Sturiale A, Ientile R, Crisafulli C, Parisi A, Catania M, Calapai G, Impalà P, Aloisi C, Squadrito F, Altavilla D, Bitto A, Tuccari G, Frisina N. Recombinant human erythropoietin stimulates angiogenesis and healing of ischemic skin wounds. Shock 2004;22(2):169-173.
125. Buemi M, Lacquaniti A, Bolignano D, Cernaro V, Campo S, Grasso G, Buemi A, Donato V, Sturiale A. Down with the erythropoietin. Long live the erythropoietin! Curr Drug Targets 2009;10(10):1028-1032.
126. Buemi M, Lacquaniti A, Maricchiolo G, Bolignano D, Campo S, Cernaro V, Sturiale A, Grasso G, Buemi A, Allegra A, Donato V, Genovese L. Regenerative medicine: Does erythropoietin have a role? Curr Pharm Des 2009;15(17):2026-2036.
127. Mu X, Urso ML, Murray K, Fu F, Li Y. Relaxin regulates MMP expression and promotes satellite cell mobilization during muscle healing in both young and aged mice. Am J Pathol 2010;177(5):2399-2410.
128. Unemori EN, Lewis M, Constant J, Arnold G, Grove BH, Normand J, Deshpande U, Salles A, Pickford LB, Erikson ME, Hunt TK, Huang X. Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites. Wound Repair Regen 2000;8(5):361-370.
129. Segal MS, Sautina L, Li S, Diao Y, Agoulnik AI, Kielczewski J, McGuane JT, Grant MB, Conrad KP. Relaxin increases human endothelial progenitor cell NO and migration and vasculogenesis in mice. Blood 2012;119(2):629-636.
130. McGuane JT, Danielson LA, Debrah JE, Rubin JP, Novak J, Conrad KP. Angiogenic growth factors are new and essential players in the sustained relaxin vasodilatory pathway in rodents and humans. Hypertension 2011;57(6):1151-1160.
131. Sturiale A, Campo S, Crascì E, Aloisi C, Buemi M. Experimental models of acute renal failure and erythropoietin: What evidence of a direct effect? Renal Fail 2007;29(3):379-386.
132. Ferlin A, Pepe A, Facciolli A, Gianesello L, Foresta C. Relaxin stimulates osteoclast differentiation and activation. Bone 2010;46(2):504-513.
133. Ferlin A, Perilli L, Gianesello L, Taglialavoro G, Foresta C. Profiling insulin like factor 3 (INSL3) signaling in human osteoblasts. PLoS One 2011;6(12):e29733.
134. Ho TY, Santora K, Chen JC, Frankshun AL, Bagnell CA. Effects of relaxin and estrogens on bone remodeling markers, receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG), in rat adjuvant-induced arthritis. Bone 2011;48(6):1346-1353.
135. Samuel CS, Tian H, Zhao L, Amento EP. Relaxin is a key mediator of prostate growth and male reproductive tract development. Lab Invest 2003;83(7):1055-1067.
136. Lamp O, Honscha KU, Jakob J, Lamp J, Schweizer S, Reischauer A, Gottschalk J, Hahn A, Ebert M, Rothemund S, Blaschzik S, Einspanier A. Investigation of the local expression of the relaxin system in canine mammary tumours. Reprod Domest Anim 2009;44(Suppl 2):224-229.
137. Radestock Y, Willing C, Kehlen A, Hoang-Vu C, Hombach-Klonisch S. Relaxin enhances S100A4 and promotes growth of human thyroid carcinoma cell xenografts. Mol Cancer Res 2010;8(4):494-506.
138. Sokol RZ, Wang XS, Lechago J, Johnston PD, Swerdloff RS. Immunohistochemical localization of relaxin in human prostate. J Histochem Cytochem 1989;37(8):1253-1255.
139. Feng S, Agoulnik IU, Bogatcheva NV, Kamat AA, Kwabi-Addo B, Li R, Ayala G, Ittmann MM, Agoulnik AI. Relaxin promotes prostate cancer progression. Clin Cancer Res 2007;13(6):1695-1702.
140. Feng S, Agoulnik IU, Li Z, Han HD, Lopez-Berestein G, Sood A, Ittmann MM, Agoulnik AI. Relaxin/RXFP1 signaling in prostate cancer progression. Ann N Y Acad Sci 2009;1160:379-380.
141. Thompson VC, Hurtado-Coll A, Turbin D, Fazli L, Lehman ML, Gleave ME, Nelson CC. Relaxin drives Wnt signaling through upregulation of PCDHY in prostate cancer. Prostate 2010;70(10):1134-1145.
142. Feng S, Agoulnik IU, Truong A, Li Z, Creighton CJ, Kaftanovskaya EM, Pereira R, Han HD, Lopez-Berestein G, Klonisch T, Ittmann MM, Sood AK, Agoulnik AI. Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer 2010;17(4):1021-1033.
143. Van Der Westhuizen ET, Summers RJ, Halls ML, Bathgate RA, Sexton PM. Relaxin receptors-New drug targets for multiple disease states. Curr Drug Targets 2007;8(1):91-104.
144. Binder C, Hagemann T, Husen B, Schulz M, Einspanier A. Relaxin enhances in-vitro invasiveness of breast cancer cell lines by up-regulation of matrix metalloproteases. Mol Hum Reprod 2002;8(9):789-796.
145. Silvertown JD, Symes JC, Neschadim A, Nonaka T, Kao JC, Summerlee AJ, Medin JA. Analog of H2 relaxin exhibits antagonistic properties and impairs prostate tumor growth. FASEB J 2007;21(3):754-765.
146. Hossain MA, Samuel CS, Binder C, Hewitson TD, Tregear GW, Wade JD, Bathgate RA. The chemically synthesized human relaxin-2 analog, B-R13/17K H2, is an RXFP1 antagonist. Amino Acids 2010;39(2):409-416.
147. Beyer I, Li Z, Persson J, Liu Y, van Rensburg R, Yumul R, Zhang XB, Hung MC, Lieber A. Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab. Mol Ther 2011;19(3):479-489.
148. Weisinger RS, Burns P, Eddie LW, Wintour EM. Relaxin alters the plasma osmolality-arginine vasopressin relationship in the rat. J Endocrinol 1993;137(3):505-510.
149. Danielson LA, Sherwood OD, Conrad KP. Relaxin is a potent renal vasodilator in conscious rats. J Clin Invest 1999;103(4):525-533.
150. Summerlee AJ, Robertson GF. Central administration of porcine relaxin stimulates drinking behaviour in rats: An effect mediated by central angiotensin II. Endocrine 1995;3(5):377-381.
151. Summerlee AJ, Hornsby DJ, Ramsey DG. The dipsogenic effects of rat relaxin: The effect of photoperiod and the potential role of relaxin on drinking in pregnancy. Endocrinology 1998;139(5):2322-2328.
152. Sinnayah P, Burns P, Wade JD, Weisinger RS, McKinley MJ. Water drinking in rats resulting from intravenous relaxin and its modification by other dipsogenic factors. Endocrinology 1999;140(11):5082-5086.
153. McKinley MJ, Mathai ML, McAllen RM, McClear RC, Miselis RR, Pennington GL, Vivas L, Wade JD, Oldfield BJ. Vasopressin secretion: Osmotic and hormonal regulation by the lamina terminalis. J Neuroendocrinol 2004;16(4):340-347.
154. Brunton PJ, Arunachalam S, Russel JA. Control of neurohypophysial hormone secretion, blood osmolality and volume in pregnancy. J Physiol Pharmacol 2008;59(Suppl 8):27-45.
155. Bogzil AH, Eardley R, Ashton N. Relaxin-induced changes in renal sodium excretion in the anesthetized male rat. Am J Physiol Regul Integr Comp Physiol 2005;288(1):R322-R328.
156. Liu C, Chen J, Sutton S, Roland B, Kuei C, Farmer N, Sillard R, Lovenberg TW. Identification of relaxin-3/INSL7 as a ligand for GPCR142. J Biol Chem 2003;278(50):50765-50770.
157. McGowan BM, Stanley SA, Ghatei MA, Bloom SR. Relaxin-3 and its role in neuroendocrine function. Ann N Y Acad Sci 2009;1160:250-255.
158. Korosi A, Baram TZ. The central corticotropin releasing factor system during development and adulthood. Eur J Pharmacol 2008;583(2-3):204-214.
159. Tanaka M, Iijima N, Miyamoto Y, Fukusumi S, Itoh Y, Ozawa H, Ibata Y. Neurons expressing relaxin 3/INSL 7 in the nucleus incertus respond to stress. Eur J Neurosci 2005;21(6):1659-1670.
160. Otsubo H, Onaka T, Suzuki H, Katoh A, Ohbuchi T, Todoroki M, Kobayashi M, Fujihara H, Yokoyama T, Matsumoto T, Ueta Y. Centrally administered relaxin-3 induces Fos expression in the osmosensitive areas in rat brain and facilitates water intake. Peptides 2010;31(6):1124-1130.
161. McGowan BM, Stanley SA, Smith KL, White NE, Connolly MM, Thompson EL, Gardiner JV, Murphy KG, Ghatei MA, Bloom SR. Central relaxin-3 administration causes hyperphagia in male Wistar rats. Endocrinology 2005;146(8):3295-3300.
162. Tanaka M. Relaxin-3/insulin-like peptide 7, a neuropeptide involved in the stress response and food intake. FEBS J 2010;277(24):4990-4997.
163. Alvarez-Jaimes L, Sutton SW, Nepomuceno D, Motley ST, Cik M, Stocking E, Shoblock J, Bonaventure P. In vitro pharmacological characterization of RXFP3 allosterism: An example of probe dependency. PLoS One 2012;7(2):e30792.
164. Ganella DE, Callander GE, Ma S, Bye CR, Gundlach AL, Bathgate RA. Modulation of feeding by chronic rAAV expression of a relaxin-3 peptide agonist in rat hypothalamus. Gene Ther 2012 [Epub ahead of print]. doi: 10.1038/gt.2012.83
165. Ponikowski P, Metra M, Teerlink JR, Unemori E, Felker GM, Voors AA, Filippatos G, Greenberg B, Teichman SL, Severin T, Mueller-Velten G, Cotter G, Davison BA. Design of the RELAXIN in acute heart failure study. Am Heart J 2012;163(2):149-155.e1.
166. Cernaro V, Lacquaniti A, Donato V, Fazio MR, Buemi A, Buemi M. Fibrosis,
167. Bell RJ, Permezel M, MacLennan A, Hughes C, Healy D, Brennecke S. A randomized, double blind, placebo-controlled trial of the safety of vaginal recombinant human relaxin for cervical ripening. Obstet Gynecol 1993;82(3):328-333.
168. Brennand JE, Calder AA, Leitch CR, Greer IA, Chou MM, MacKenzie IZ. Recombinant human relaxin as a cervical ripening agent. Br J Obstet Gynaecol 1997;104(7):775-780.
169. Seibold JR, Clements PJ, Furst DE, Mayes MD, McCloskey DA, Moreland LW, White B, Wigley FM, Rocco S, Erikson M, Hannigan JF, Sanders ME, Amento EP. Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosis. J Rheumatol 1998;25(2):302-307.
170. Seibold JR, Korn JH, Simms R, Clements PJ, Moreland LW, Mayes MD, Furst DE, Rothfield N, Steen V, Weisman M, Collier D, Wigley FM, Merkel PA, Csuka ME, Hsu V, Rocco S, Erikson M, Hannigan J, Harkonen WS, Sanders ME. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000;132(11):871-879.
171. http://clinicaltrials.gov/ct2/show/NCT00333307?term=relaxin&rank=5
172. Dschietzig T, Teichman S, Unemori E, Wood S, Boehmer J, Richter C, Baumann G, Stangl K. First clinical experience with intravenous recombinant human relaxin in compensated heart failure. Ann N Y Acad Sci 2009;1160:387-392.
173. Weiss G, Teichman S, Stewart D, Nader D, Wood S, Unemori E. A randomized, double-blind, placebo-controlled trial of relaxin for cervical ripening in post-delivery date pregnancies. Ann N Y Acad Sci 2009;1160:385-386.
174. Khanna D, Clements PJ, Furst DE, Korn JH, Ellman M, Rothfield N, Wigley FM, Moreland LW, Silver R, Kim YH, Steen VD, Firestein GS, Kavanaugh AF, Weisman M, Mayes MD, Collier D, Csuka ME, Simms R, Merkel PA, Medsger TA Jr, Sanders ME, Maranian P, Seibold JR; Relaxin Investigators and the Scleroderma Clinical Trials Consortium. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009;60(4):1102-1111.
175. Dschietzig T, Teichman S, Unemori E, Wood S, Boehmer J, Richter C, Baumann G, Stangl K. Intravenous recombinant human relaxin in compensated heart failure: A safety, tolerability, and pharmacodynamic trial. J Card Fail 2009;15(3):182-190.
176. McGorray SP, Dolce C, Kramer S, Stewart D, Wheeler TT. A randomized, placebo-controlled clinical trial on the effects of recombinant human relaxin on tooth movement and short-term stability. Am J Orthod Dentofacial Orthop 2012;141(2):196-203.